Homozygosity for factor V leiden leads to enhanced thrombosis and atherosclerosis in mice

Circulation

Volumn 111, Issue 14, 2005, Pages 1822-1825

  Eitzman, Daniel T ^a   Westrick, Randal J ^b   Shen, Yuechun ^a   Bodary, Peter F ^a   Gu, Shufang ^a   Manning, Sara L ^a   Dobies, Sarah L ^a   Ginsburg, David ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Coagulation; Fibrinogen; Thrombosis

Indexed keywords

APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 5 LEIDEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTERY THROMBOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CAROTID ARTERY INJURY; CAROTID ARTERY THROMBOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS BREEDING; GENE MUTATION; GENETIC PREDISPOSITION; HETEROZYGOSITY; HOMOZYGOSITY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; AORTIC DISEASES; ARTERIOSCLEROSIS; BONE MARROW TRANSPLANTATION; CAROTID ARTERY INJURIES; CAROTID ARTERY THROMBOSIS; DISEASE MODELS, ANIMAL; FACTOR V; FIBRINOGEN; HOMOZYGOTE; MICE; MICE, MUTANT STRAINS; PHOTOCHEMISTRY; THROMBIN; THROMBOSIS;

EID: 17144373675     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000160854.75779.E8     Document Type: Article

References (31)

1. Svensson PJ. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.
2. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulation protein C pathway defective in majority of thrombophilic patients. Blood. 1993;82:1989-1993.
3. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP. Venous thrombosis due to poor anticoagulant response to activated protein C. Lancet. 1993;342:1503-1506.
4. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men [see comments]. N Engl J Med. 1995;332:912-17.
5. Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <50 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol. 2000;36:717-722.
6. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, Bayliss P, Peake IR, Miller GJ. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997;78:1426-1429.
7. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, Dardik R, Baron Z, Seligsohn U. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood. 1999;2186-2190.
8. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women [see comments]. Blood. 1997;89:2817-2821.
9. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002;100:3-10.
10. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood. 1998;92:3035-3041.
11. Yang TL, Pipe SW, Yang A, Ginsburg D. Biosynthetic origin and functional significance of murine platelet factor V. Blood. 2003;102:2851-2855.
12. Sun H, Yang TL, Yang A, Wang X, Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood. 2003;102:2856-2861.
13. Cui J, Eitzman DT, Westrick RJ, Christie PD, Xu Z, Yang A, Purkayastha A, Yang TL, Metz AL, Gallagher KP, Tyson J, Rosenberg RD, Ginsburg D. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000;96:4222-4226.
14. Sjoland H, Eitzman DT, Gordon D, Westrick RJ, Nabel EG, Ginsburg D. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol. 2000;20:846-852.
15. Eitzman DT, Westrick RJ, Nabel EG, Ginsburg D. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood. 2000;95:577-580.
16. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, Abe A, Shaffer-Hartman J, Shayman JA. Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol. 2003;14:298-302.
17. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, Eitzman DT. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation. 2001;103:3044-3046.
18. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536-1538.
19. 506 of factor V. Lancet. 1994;343:1535-1536.
20. Makris TK, Krespi PG, Hatzizacharias AN, Gialeraki AE, Anastasiadis G, Triposkiadis FK, Mandalaki T, Kyriakidis MK. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens. 2000;13(pt 1):61-65.
21. Vandeplassche G, Bemier M, Kusama BM. Singlet oxygen and myocardial injury: ultrastructural, cytochemical and electrocardiographic consequences of photoactivation of rose bengal. J Mol Cell Cardiol. 1990;22:287-301.
22. White CR, Chang LY, Crapo J, Ku D, Gianturco SH, Gore J, Freeman BA. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci U S A. 1995;91:1044-1048.
23. Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods. 1991;25:303-318.
24. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest. 2002;109:213-219.
25. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2000;20:1831-1834.
26. Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA. 2002;287:1706-1709.
27. Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood. 1998;91:2818-2829.
28. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 2000;96:4212-4215.
29. Rosenberg RD, Aird WC. Mechanisms of disease: vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med. 1999;340:1555-1564.
30. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A. 1998;95:12591-12595.
31. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Degen JL. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. J Clin Invest. 1998;101:1184-1194.